GlassScriptPhysician profile
Marlon C Decastro
NPI 1780643270
$3,865.80
in general payments reported to CMS, 2019-2025
37 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,776 · 2020: $380 · 2021: $57.49 · 2022: $179 · 2023: $858 · 2024: $277 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $733.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $362.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $334.46 | 2019-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.99 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $254.85 | 2019-2024 | Breztri, Airsupra |
| Radius Health, INC. | $238.67 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $189.48 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $154.39 | 2019-2023 | Veozah, Myrbetriq |
| Novo Nordisk INC | $139.73 | 2019-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $130.07 | 2019-2025 | Eliquis |
| Avanir Pharmaceuticals, INC. | $110.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $77.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.83 | 2023-2025 | |
| Allergan, INC. | $60.44 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlon Decastro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.